KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Capital Leases (2017 - 2026)

Moderna (MRNA) has disclosed Capital Leases for 10 consecutive years, with $13.0 million as the latest value for Q1 2026.

  • For Q1 2026, Capital Leases fell 62.86% year-over-year to $13.0 million; the TTM value through Mar 2026 reached $13.0 million, down 62.86%, while the annual FY2025 figure was $20.0 million, 48.72% down from the prior year.
  • Capital Leases hit $13.0 million in Q1 2026 for Moderna, down from $20.0 million in the prior quarter.
  • Across five years, Capital Leases topped out at $922.0 million in Q3 2022 and bottomed at $13.0 million in Q1 2026.
  • Average Capital Leases over 5 years is $463.9 million, with a median of $575.0 million recorded in 2023.
  • Year-over-year, Capital Leases surged 368.12% in 2022 and then tumbled 95.84% in 2025.
  • Moderna's Capital Leases stood at $912.0 million in 2022, then tumbled by 36.95% to $575.0 million in 2023, then plummeted by 93.22% to $39.0 million in 2024, then plummeted by 48.72% to $20.0 million in 2025, then plummeted by 35.0% to $13.0 million in 2026.
  • According to Business Quant data, Capital Leases over the past three periods came in at $13.0 million, $20.0 million, and $26.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.